Traherne J A, Jiang W, Valdes A M, Hollenbach J A, Jayaraman J, Lane J A, Johnson C, Trowsdale J, Noble J A
Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, UK.
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
Genes Immun. 2016 Jan-Feb;17(1):8-12. doi: 10.1038/gene.2015.44. Epub 2015 Oct 22.
Classical human leukocyte antigens (HLA) genes confer the strongest, but not the only, genetic susceptibility to type 1 diabetes. Killer cell immunoglobulin-like receptors (KIR), on natural killer (NK) cells, bind ligands including class I HLA. We examined presence or absence, with copy number, of KIR loci in 1698 individuals, from 339 multiplex type 1 diabetes families, from the Human Biological Data Interchange, previously genotyped for HLA. Combining family data with KIR copy number information allowed assignment of haplotypes using identity by descent. This is the first disease study to use KIR copy number typing and unambiguously define haplotypes by gene transmission. KIR A1 haplotypes were positively associated with T1D in the subset of patients without the high T1D risk HLA genotype, DR3/DR4 (odds ratio=1.29, P=0.0096). The data point to a role for KIR in type 1 diabetes risk in late-onset patients. In the top quartile (age of onset>14), KIR A2 haplotype was overtransmitted (63.4%, odds ratio=1.73, P=0.024) and KIR B haplotypes were undertransmitted (41.1%, odds ratio=0.70, P=0.0052) to patients. The data suggest that inhibitory 'A' haplotypes are predisposing and stimulatory 'B' haplotypes confer protection in both DR3/DR4-negative and late-onset patient groups.
经典人类白细胞抗原(HLA)基因赋予1型糖尿病最强但并非唯一的遗传易感性。自然杀伤(NK)细胞上的杀伤细胞免疫球蛋白样受体(KIR)与包括I类HLA在内的配体结合。我们检测了来自人类生物数据交换中心的339个1型糖尿病家系的1698名个体中KIR基因座的有无及拷贝数,这些个体之前已进行过HLA基因分型。将家系数据与KIR拷贝数信息相结合,可通过系谱同一性来确定单倍型。这是第一项使用KIR拷贝数分型并通过基因传递明确界定单倍型的疾病研究。在没有高1型糖尿病风险HLA基因型DR3/DR4的患者亚组中,KIR A1单倍型与1型糖尿病呈正相关(优势比=1.29,P=0.0096)。数据表明KIR在晚发型患者的1型糖尿病风险中起作用。在年龄四分位数最高组(发病年龄>14岁)中,KIR A2单倍型过度传递给患者(63.4%,优势比=1.73,P=0.024),而KIR B单倍型传递不足(41.1%,优势比=0.70,P=0.0052)。数据表明,在DR3/DR4阴性和晚发型患者组中,抑制性“A”单倍型具有易感性,而刺激性“B”单倍型具有保护作用。